● Recruiting

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Condition: Collecting Duct Carcinoma · Sponsor: Peking University Cancer Hospital & Institute

PhasePhase 2

Planned participants30

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.

This description comes directly from the study's public registry record.

Talk to the study team

Xinan Sheng, MD. · +86-10-88196348 · doctor_sheng@126.com

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute	Beijing, Beijing Municipality, China	Recruiting
Beijing Cancer Hospital	Beijing, Beijing Municipality, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06211114